• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Candesartan Celexetil Ester

Candesartan Celexetil Ester

Product ID C0254
Cas No. 145040-37-5
Purity ≥98%
Product Unit SizeCostQuantityStock
100 mg $101.00 In stock
250 mg $180.00 In stock
1 g $546.90 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Candesartan is an inhibitor of the angiotensin II type 1 receptor (AT1) that displays antihypertensive, cardioprotective, nephroprotective, and potentially antiviral activities. In vivo, candesartan increases renal blood blow and decreases renal vascular resistance, glomerular filtration rate, and filtration fraction. Candesartan also decreases NADPH oxidase activity and levels of TGF-β, inhibiting calcium oxalate crystal deposition and kidney stone formation. In animal models of pressure overload-induced cardiac remodeling, candesartan downregulates Smad3 and fibronectin, upregulates Smad7, and inhibits matrix metalloproteinase 9 (MMP9) and the epithelial-to-mesenchymal transition (EMT), preventing collagen deposition, left ventricular remodeling, and decreases in left ventricular ejection fraction. Additionally, this compound downregulates expression of VEGFR2, decreasing retinal neovascularization without inhibiting total angiogenesis. Separately, candesartan may inhibit the interaction between lens epithelium-derived growth factor (LEDGF) and HIV-1 integrase, exhibiting potential as a treatment for HIV.

Product Info

Cas No.

145040-37-5

Purity

≥98%

Formula

C33H34N6O6

Formula Wt.

610.66

Chemical Name

1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole- 4-carboxylate

IUPAC Name

1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole- 4-carboxylate

Synonym

Candesartan 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester

Solubility

Chloroform, slightly soluble in methanol, ethanol (3 mg/ml), DMSO (30 mg/ml).

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

C0254 MSDS PDF

Info Sheet

C0254 Info Sheet PDF

Brochures

Antivirals Booklet

References

Patinha D, Fasching A, Pinho D, et al. Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independently of adenosine type I receptors. Am J Physiol Renal Physiol. 2013 Mar 1;304(5):F614-22. PMID: 23283998.

Hu G, Li X, Sun X, et al. Identification of old drugs as potential inhibitors of HIV-1 integrase - human LEDGF/p75 interaction via molecular docking. J Mol Model. 2012 Dec;18(12):4995-5003. PMID: 22733274.

Nakamura S, Tsuruma K, Shimazawa M, et al. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression. Eur J Pharmacol. 2012 Jun 15;685(1-3):8-14. PMID: 22543084.

Yu H, Zhao G, Li H, et al. Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. Gene. 2012 Apr 15;497(2):301-6. PMID: 22326534.

Yoshioka I, Tsujihata M, Akanae W, et al. Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys. Urology. 2011 Apr;77(4):1007.e9-1007.e14. PMID: 21256551.

Wada T, Inada Y, Ojima M, et al. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res. 1996 Jun;19(2):75-81. Erratum in: Hypertens Res 1996 Sep;19(3):221. PMID: 10968199.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M5794

    Moxifloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV, topoisomeras...

    ≥98%
  • G5322

    GNF-5

    Abl inhibitor.

    ≥99%
  • S3346

    Silodosin

    α1A-adrenergic antagonist.

    ≥98%
  • P0006

    Pituitary Adenylate Cyclase-activating Polypeptide (1-38), human, sheep, rat

    Endogenous peptide, involved in paracrine and a...

    ≥95%
  • C179602

    CEP-28122

    ALK inhibitor.

    ≥98%
  • O7377

    Osthole

    O-methylated coumarin; Ca2+ channel blocker.

    ≥98%
  • G8103

    Guanylin, human

    Endogenous peptide hormone; guanyl cyclase C ag...

    ≥95%
  • T1675

    Teriparatide Acetate

    Synthetic peptide hormone, PTH analog; PTH1R ag...

    ≥95%
  • C0044

    CAL101

    p110δ PI3K inhibitor.

    ≥99%
  • B0396

    BAY80-6946

    p110α PI3K inhibitor.

    ≥98%
  • C2957

    Cholesterol

    Endogenous sterol component of animal cell memb...

    ≥97%
  • L8248

    Lumiracoxib

    NSAID; COX-2 inhibitor.

    ≥98%
  • A5373

    Anisomycin

    Peptidyl transferase inhibitor, protein transla...

    ≥98%
  • C3352

    Cinacalcet Hydrochloride

    Ca2+-sensing receptor agonist.

    ≥99%
  • T1644

    Telmisartan

    AT-II antagonist, PPARγ/δ modulator.

    ≥98%
  • A9712

    AZD-6482

    p110β PI3K inhibitor.

    ≥98%
  • S8243

    Sulbactam Sodium

    β-lactamase inhibitor.

    ≥98%
  • P3542

    PIK-93

    p110α and p110γ PI3K inhibitor.

    ≥98%
  • H000051

    H-151

    STING antagonist

    ≥99%
  • C3208

    Ciclopirox Olamine

    Hydroxypyridone, metal ion chelator; mTOR inhib...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only